reported that CXCL10 and CXCR3 were increased in GSCs and a malignant glioma model, celecoxib inhibited the expression of CCL2 and CXCR3 in an NF‐κB‐dependent manner, and in addition, silencing of CCL2 led to a decrease in GSC viability. Here, CCL2 is linked to malignant glioma.